1. Clinical Overview

Molecule: Tetrapeptide D-Arg–Dmt–Lys–Phe-NH₂ (Dmt = dimethyltyrosine)

Classification: Mitochondrial-targeted peptide (MTP) • Cardiolipin-binding stabilizer • Cell-rescue molecule

One of the most potent mitochondrial-protective peptides developed. Rapidly enters cells, concentrates in mitochondria, binds cardiolipin — a phospholipid crucial for membrane curvature, respiration, ATP production, and electron transport stability. Distinct from MOTS-c or 1MQ.

2. Mechanisms of Action

2.1 Cardiolipin Stabilization

Cardiolipin is essential for ETC function, ATP production, membrane structure, cytochrome c anchoring. SS-31 restores ETC efficiency, inner membrane curvature, cytochrome c electron transfer (preventing apoptosis).

2.2 Reduced Mitochondrial ROS

Decreases ROS at complexes I & III, prevents oxidative damage to lipids/proteins, improves redox balance. Enhanced cellular resilience.

2.3 Enhanced ATP Production

Normalizes ETC efficiency: increased ATP yield, respiratory capacity, cellular energy. Benefits aging, fatigue, heart/skeletal muscle function.

2.4 Anti-Apoptotic

Prevents pathologic cytochrome c release, caspase cascade, mitochondrial-induced apoptosis. Neuroprotection, cardioprotection, tissue recovery.

2.5 Mitochondrial Dynamics

Fusion/fission balance, quality control, mitophagy efficiency, reduced cellular senescence.

3. Clinical Applications

3.1 Energy & Fatigue

Improved ATP, exercise tolerance, energy stability, muscle O₂ utilization. CFS, post-viral fatigue, long-haul stress, aging decline.

3.2 Musculoskeletal & Performance

VO2 max, endurance, strength recovery, lactate threshold. Athletes, older adults, mitochondrial myopathy.

3.3 Cardiac Protection

Improved LV function, reduced ischemia-reperfusion injury, cardiac mitochondrial respiration. Heart disease risk, aging heart, post-exercise strain. Not FDA-approved for cardiac.

3.4 Neuroprotection

Reduces neuronal oxidative stress, supports mitochondrial integrity, protects against excitotoxicity. Cognitive decline, post-TBI, neurodegenerative support.

3.5 Organ Protection

Reduces oxidative injury during ischemia, toxin exposure, hypoxia. Kidney, liver, whole-body resilience.

4. Administration & Protocols

4.1 SC (Standard)

Fatigue/Energy: 5 mg SC daily, 5 on/2 off, 4–8 weeks
Performance: 10–15 mg SC pre-training (1–3 hrs before)
Anti-Aging Maintenance: 5–10 mg SC 2–3×/week

4.2 IM

10 mg IM 2–3×/week. Suitable for sarcopenia/severe mitochondrial decline.

4.3 IV Infusion (Advanced)

Dose: 10–40 mg IV over 30–60 min
Frequency: Weekly × 4–8 weeks
Fastest systemic mitochondrial response.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ MOTS-c: AMPK + metabolic flexibility + direct mito repair — profound synergy
+ NAD+: Coenzyme for ATP + respiration efficiency — longevity, cognition, fatigue
+ SLU-PP-332 / 5-Amino-1MQ: Thermogenesis + metabolic acceleration
+ REVIVE™: Full-spectrum mitochondrial optimization
+ BPC-157 / TB-500: Cellular energy + tissue repair for injury recovery

6. Clinical Decision Trees

Tree 1 — Is SS-31 Indicated?

Fatigue / mitochondrial dysfunction / low stamina? → YES

Performance / endurance improvement? → YES

Anti-aging protocol? → YES — synergistic with NAD+, MOTS-c, Epitalon

Cardiac or neurocognitive decline? → YES — supports mitochondrial repair

Primary goal weight loss? → Supportive; 1MQ/SLU-PP-332 primary

Tree 2 — Route & Dose

Rapid improvement needed → IV infusion

Steady-state optimization → 5–10 mg SC daily

Performance enhancement → 10–15 mg SC pre-training

Long-term anti-aging → 5–10 mg SC 2–3×/week

7. Integrated Archetypes

A — Mitochondrial Repair & Energy

SS-31 10 mg SC daily + NAD+ daily + REVIVE™ AM + Glutathione IV weekly
Outcome: Improved ATP, decreased fatigue, enhanced resilience.

B — Athletic Endurance

SS-31 10–15 mg SC pre-training + MOTS-c 2×/week + SLU-PP-332 daily + electrolyte/creatine
Outcome: Increased VO2 max, endurance, faster recovery.

C — Anti-Aging & Longevity

SS-31 weekly (SC/IV) + Epitalon quarterly + NAD+ + MOTS-c weekly + REVIVE™ daily
Outcome: Improved biological age, reduced oxidative stress.

D — Post-Viral / Post-Inflammatory Fatigue

SS-31 5–10 mg SC daily × 4–6 weeks + NAD+ IV + Glutathione IV + DSIP sleep repair
Outcome: Restored cellular energy, NS stability, stamina.

8. Expected Timeline

Day 1–3: Elevated energy, reduced brain fog
Week 1–2: Improved stamina, decreased fatigue
Week 3–4: Significant mitochondrial/exercise improvements
Week 4–8: Peak performance & anti-aging effects
Long-term: Cellular resilience & improved biological age

9. Contraindications

Absolute

Known hypersensitivity
Pregnancy / Lactation

Relative

Active cancer (may theoretically assist tumor metabolism)
Severe cardiac arrhythmias (monitor closely)

10. Adverse Effects

Well tolerated. Mild: temporary headache, warmth/flushing, mild nausea (IV), injection-site irritation, transient fatigue during early adaptation. No serious AEs widely reported in clinical trials.

11. Monitoring

Fatigue scales
VO2 max / endurance metrics
HRV
Blood glucose
Sleep quality
Inflammatory markers
Mitochondrial function tests (optional)

Legal Disclaimer

This document is provided solely for educational and informational purposes. SS-31 (Elamipretide / Bendavia / MTP-131) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — SS-31 (Elamipretide)

Foundational Discovery

1. Szeto, H. H., & Schiller, P. W. Mitochondria-targeted Szeto–Schiller peptides. Biochem Biophys Res Commun, 293(3), 852–857 (2002).

2. Szeto, H. H. Cardiolipin binding & electron transport stabilization. Chem Biol, 21(2), 182–195 (2014).

3. Birk, A. V., et al. Elamipretide targets cardiolipin cristae. Sci Transl Med, 5(211), 211ra158 (2013).

4. Chavez, J. D., et al. Cardiolipin regulates respiratory supercomplexes. Cell Metabolism, 28(6), 947–957 (2018).

Mitochondrial Protection & Bioenergetics

5. Szeto, H. H. Cytoprotective peptides: ROS and ATP. Pharmacol Ther, 127(1), 123–131 (2010).

6. Birk, A. V., & Szeto, H. H. Oxidative stress and mitochondrial coupling. Antioxid Redox Signal, 10(3), 601–612 (2010).

7. Zhao, K., et al. SS peptides prevent swelling/apoptosis. PNAS, 101(8), 13603–13608 (2004).

8. Szeto, H. H. Cardiolipin protection & supercomplex stabilization. Aging Cell, 19(7), e13185 (2020).

Cardiac Protection

9. Cho, J., et al. Reduces infarct size in ischemia-reperfusion. JACC Basic Transl Sci, 1(6), 353–365 (2016).

10. Kloner, R. A., et al. SS-31 in acute MI. Circ Res, 111(3), 311–321 (2012).

11. Sabbah, H. N., et al. Elamipretide in HFrEF. Eur J Heart Fail, 18(3), 340–348 (2016).

12. Daubert, M. A., et al. Phase 2 HFrEF trial. JAMA Cardiol, 5(5), 549–556 (2020).

Renal Protection

13. Birk, A. V., et al. Renal mitochondrial function. Am J Physiol Renal, 303(1), F90–F102 (2012).

14. Sweetwyne, M. T., et al. Reverses mito fragmentation in nephropathy. Kidney Int, 98(6), 1380–1395 (2020).

15. Szeto, H. H., et al. Prevents CKD progression. JASN, 27(11), 3290–3298 (2016).

Muscle & Aging

16. Siegel, M. P., et al. Skeletal muscle energetics in aging. Aging Cell, 12(5), 763–771 (2013).

17. Campbell, M. D., et al. Reverses dysfunction in aging human muscle. Aging Cell, 18(2), e12915 (2019).

18. McCully, K. K., et al. ATP in mitochondrial myopathy. Muscle Nerve, 60(6), 693–702 (2019).

Neuroprotection

19. Zhao, K., et al. Protects neurons from oxidative damage. J Neurochem, 94(1), 169–179 (2005).

20. Wu, H., et al. Reduces neuroinflammation in CNS injury. Exp Neurol, 347, 113894 (2022).

21. Thomas, R., et al. Reduces amyloid toxicity in AD models. Aging Cell, 19(8), e13109 (2020).

Ocular & Retinal

22. Jarrett, S. G., et al. Protects photoreceptors. PNAS, 107(13), 4905–4910 (2010).

23. Wong, R., et al. Retinal function in AMD. Invest Ophthalmol Vis Sci, 59(6), 2296–2307 (2018).

24. Toussaint, B., et al. Phase 1/2 for geographic atrophy. Ophthalmol Retina, 5(2), 94–106 (2021).

Mitochondrial Myopathies

25. Karaa, A., et al. MMPOWER clinical trials. Lancet, 391(10123), 1–11 (2018).

26. Siegler, M. E., et al. Elamipretide in Barth syndrome. Orphanet J Rare Dis, 13, 4 (2018).

27. Bradford, R., et al. Supercomplex stabilization. Cell Reports, 38(9), 110535 (2022).

Inflammation & Immune

28. Chacko, B. K., et al. Suppresses ROS and inflammatory signaling. Free Radic Biol Med, 52(5), 956–966 (2012).

29. Tarrago, M. G., et al. SS-31 immunometabolic role. Front Aging, 3, 667704 (2021).

Pharmacokinetics & Safety

30. Dodelet, V., et al. PK/biodistribution in humans. Clin Pharmacokinet, 58(7), 1–12 (2019).

31. U.S. FDA. Elamipretide regulatory filings. FDA CDER, 2017–2023.

32. Varga, Z. V., et al. Safety considerations. Pharmacol Ther, 233, 108022 (2022).